RCM
CSCI

Rotella Capital Management’s COSCIENS Biopharma Inc. Common Stock CSCI Stock Holding History

Rotella Capital Management’s Portfolio CSCI Stock Details CSCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-2
Closed -$20K – 407
2014
Q2 		$20K Buy
+2
New +$22.3K 0.02% 363
2013
Q3 		– Sell
-2
Closed -$30K – 160
2013
Q2 		$30K Buy
+2
New +$37.9K 0.1% 119

Other funds holding CSCI

NCCM
Nine Chapters Capital Management Short Hills, New Jersey $45.4M AUM 14.43% 1-Year Est. Return
AG
Aperio Group Sausalito, California $33.8B AUM 31.46% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $54.7B AUM 26.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Rotella Capital Management's CSCI Position: Q3 2014 in Review

Rotella Capital Management sold out of COSCIENS Biopharma Inc. Common Stock (CSCI) in Q3 2014, closing a stake of 2 shares — an estimated $20K sold.

Rotella Capital Management first reported a position in CSCI in Q2 2013 and held it in 2 quarters. The position peaked at $30K in Q2 2013. 13 funds tracked by Wall St. Rank hold CSCI as of Q3 2014.

  • Rotella Capital Management reported no remaining COSCIENS Biopharma Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Rotella Capital Management sold 2 COSCIENS Biopharma Inc. Common Stock shares in Q3 2014, an estimated $20K.
  • Rotella Capital Management first reported a position in COSCIENS Biopharma Inc. Common Stock in Q2 2013 and held it in 2 quarters.
  • Rotella Capital Management's COSCIENS Biopharma Inc. Common Stock position peaked at $30K in Q2 2013.
  • 13 funds tracked by Wall St. Rank held COSCIENS Biopharma Inc. Common Stock as of Q3 2014.

Based on Rotella Capital Management's 13F filing for Q3 2014, filed 14 Nov 2014.